Keratoacanthoma - Ceratoacantoma
☆ AI Dermatology — Free Service
Nos resultados do Stiftung Warentest de 2022 da Alemanha, a satisfação do consumidor com o ModelDerm foi apenas ligeiramente inferior do que com as consultas pagas de telemedicina.
Nos resultados do Stiftung Warentest de 2022 da Alemanha, a satisfação do consumidor com o ModelDerm foi apenas ligeiramente inferior do que com as consultas pagas de telemedicina.
Ceratoacantoma típico (Keratoacanthoma)
relevance score : -100.0%
ReferencesKeratoacanthoma (KA) é um tumor cutâneo frequente, conhecido por seu rápido crescimento e pela capacidade de regredir espontaneamente. Geralmente ocorre em homens mais velhos, de pele clara, com histórico de dano solar. Embora a remoção cirúrgica por excisão ou cirurgia micrográfica de Mohs seja o tratamento de escolha, existem outras opções terapêuticas disponíveis.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) é um tumor de baixo grau que se origina em certas glândulas da pele e se assemelha ao squamous cell carcinoma (SCC) ao microscópio. Há um debate contínuo sobre se o KA deve ser classificado como uma forma de CEC invasivo.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Carcinoma cutâneo de células escamosas (cSCC) é o segundo tipo de câncer mais comum nas pessoas, especialmente entre os idosos. A cirurgia é normalmente usada para tratar o cSCC, mas, para alguns pacientes que não podem ser operados ou que optam por não fazê‑lo, outras opções, como tratamentos intralesionais, podem ser consideradas. Tratamentos intralesionais tradicionais (methotrexate ou 5‑fluorouracil) têm sido usados, mas há pesquisas em andamento sobre novas abordagens, como imunoterapia intralesional e viroterapia oncolítica. Aqui, veremos diferentes tratamentos intralesionais para cSCC, desde métodos clássicos até estratégias de ponta.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
No microscópio, o Ceratoacantoma (Keratoacanthoma) assemelha‑se muito ao carcinoma de células escamosas. Embora alguns patologistas classifiquem o Ceratoacantoma (Keratoacanthoma) como uma entidade distinta e não como malignidade, cerca de 6 % dos casos clínicos e histológicos evoluem para carcinomas de células escamosas invasivos e agressivos.
○ Diagnóstico e Tratamento
#Dermoscopy
#Skin biopsy